Chemokine Therapeutics Corp., a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, has been granted US Patent No. 7,378,098.

Patent No. 7,378,098 entitled "CXC Chemokine Receptor 4 Agonist Peptides" is related to treatment of patients in need of bone marrow or stem cell transplantation. This patent is based on evidence that treatment with SDF-1 chemokine analog prevents reduction of normal bone marrow stem cells and restores white blood cells, which reduce susceptibility to infections in cancer patients following chemotherapy treatment.